These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 15744590)

  • 1. Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study.
    Schmid P; Schweigert M; Beinert T; Flath B; Sezer O; Possinger K
    Invest New Drugs; 2005 Mar; 23(2):139-46. PubMed ID: 15744590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study.
    Akrivakis K; Schmid P; Flath B; Schweigert M; Sezer O; Mergenthaler HG; Possinger K
    Anticancer Drugs; 1999 Jul; 10(6):525-31. PubMed ID: 10885899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
    Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
    Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.
    Brand R; Capadano M; Tempero M
    Invest New Drugs; 1997; 15(4):331-41. PubMed ID: 9547676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors.
    Maurel J; Zorrilla M; Puertolas T; Antón A; Herrero A; Artal A; Alonso V; Martinez-Trufero J; Puertas MM
    Anticancer Drugs; 2001 Oct; 12(9):713-7. PubMed ID: 11593051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
    Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
    Ryan DP; Lynch TJ; Grossbard ML; Seiden MV; Fuchs CS; Grenon N; Baccala P; Berg D; Finkelstein D; Mayer RJ; Clark JW
    Cancer; 2000 Jan; 88(1):180-5. PubMed ID: 10618622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
    Amarantidis K; Houhouli K; Papatheodorou K; Miloussis A; Matthaios D; Chatzaki E; Lyrantzopoulos N; Tsaroucha A; Tentes A; Kakolyris S
    Oncol Res; 2006; 16(6):281-7. PubMed ID: 17476973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study.
    Athanasiadis A; Roussos G; Papakostoulis T; Athanasiadou DC; Stathopoulos GP
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):653-8. PubMed ID: 15937714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent gemcitabine is active in previously treated metastatic breast cancer.
    Spielmann M; Llombart-Cussac A; Kalla S; Espié M; Namer M; Ferrero JM; Diéras V; Fumoleau P; Cuvier C; Perrocheau G; Ponzio A; Kayitalire L; Pouillart P
    Oncology; 2001; 60(4):303-7. PubMed ID: 11408796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
    Touroutoglou N; Gravel D; Raber MN; Plunkett W; Abbruzzese JL
    Ann Oncol; 1998 Sep; 9(9):1003-8. PubMed ID: 9818075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
    Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
    Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer.
    Schmid P; Akrivakis K; Flath B; Grosse Y; Sezer O; Mergenthaler HG; Possinger K
    Anticancer Drugs; 1999 Aug; 10(7):625-31. PubMed ID: 10507311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
    Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label phase 1 dose-escalation clinical trial of a single intravenous administration of gemcitabine in dogs with advanced solid tumors.
    Marconato L; Finotello R; Bonfanti U; Dacasto M; Beatrice L; Pizzoni S; Leone VF; Balestra G; Furlanello T; Rohrer Bley C; Aresu L
    J Vet Intern Med; 2015; 29(2):620-5. PubMed ID: 25818216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine.
    Ulrich-Pur H; Kornek GV; Fiebiger W; Schüll B; Raderer M; Scheithauer W
    Oncology; 2001; 60(4):313-5. PubMed ID: 11408798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels.
    Pollera CF; Ceribelli A; Crecco M; Oliva C; Calabresi F
    Invest New Drugs; 1997; 15(2):115-21. PubMed ID: 9220290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
    Bass AJ; Gockerman JP; Hammett E; DeCastro CM; Adams DJ; Rosner GL; Payne N; Davis P; Foster T; Moore JO; Rizzieri DA
    J Clin Oncol; 2002 Jul; 20(13):2995-3000. PubMed ID: 12089230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
    Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
    Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of gemcitabine using a once every 2 weeks schedule.
    Vermorken JB; Guastalla JP; Hatty SR; Seitz DE; Tanis B; McDaniels C; Clavel MD
    Br J Cancer; 1997; 76(11):1489-93. PubMed ID: 9400947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.